“这是价值事务所的第1988篇原创文章”在前一篇讲CXO的文章中，所长给大家介绍了现如今CXO的一个极大预期差，即绝大多数人还只将 CXO 视为创新药产业链的配套环节，是跟班的角色，却忽视其早已通过努力达成了类似Biotech“ License-out ”的效果，再叠加其投资版图，已然成为创新药产业链价值分配的最核心玩家。甚至在 AI 加速药物发现的未来，这种多管线、高成功率的优势还将进一步放大，...
Source Link“这是价值事务所的第1988篇原创文章”在前一篇讲CXO的文章中，所长给大家介绍了现如今CXO的一个极大预期差，即绝大多数人还只将 CXO 视为创新药产业链的配套环节，是跟班的角色，却忽视其早已通过努力达成了类似Biotech“ License-out ”的效果，再叠加其投资版图，已然成为创新药产业链价值分配的最核心玩家。甚至在 AI 加速药物发现的未来，这种多管线、高成功率的优势还将进一步放大，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.